Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
(NASDAQ:BIIB) BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB), today announced data from Phase 1/2a and open-label extension (OLE) studies of zorevunersen that support the potential for zorevunersen to be the first disease-modifying medicine for Dravet syndrome. Findings were presented at the 36th International Epil
Related Questions
How will the Phase 1/2a results for zorevunersen affect Biogen's valuation and upcoming earnings guidance?
What are the potential regulatory timelines and market exclusivity for a disease‑modifying therapy in Dravet syndrome compared to existing treatments?
How might this partnership with Stoke Therapeutics influence Biogen's pipeline diversification and competitive positioning in the rare neurological space?